PL356261A1 - Związki chemiczne - Google Patents

Związki chemiczne

Info

Publication number
PL356261A1
PL356261A1 PL00356261A PL35626100A PL356261A1 PL 356261 A1 PL356261 A1 PL 356261A1 PL 00356261 A PL00356261 A PL 00356261A PL 35626100 A PL35626100 A PL 35626100A PL 356261 A1 PL356261 A1 PL 356261A1
Authority
PL
Poland
Prior art keywords
piperazine compounds
piperazine
compounds
Prior art date
Application number
PL00356261A
Other languages
English (en)
Other versions
PL201191B1 (pl
Inventor
Giuseppe Alvaro
Fabio Romano Di
Riccardo Giovannini
Giuseppe Guercio
Yves St-Denis
Antonella Ursini
Original Assignee
Glaxo Group Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Limited filed Critical Glaxo Group Limited
Publication of PL356261A1 publication Critical patent/PL356261A1/pl
Publication of PL201191B1 publication Critical patent/PL201191B1/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/04—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
PL356261A 1999-10-07 2000-10-05 Piperazynowa pochodna i jej zastosowanie, zawierająca ją farmaceutyczna kompozycja oraz sposób wytwarzania piperazynowej pochodnej PL201191B1 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9923748.9A GB9923748D0 (en) 1999-10-07 1999-10-07 Chemical compounds
PCT/EP2000/009722 WO2001025219A2 (en) 1999-10-07 2000-10-05 Piperazine compounds

Publications (2)

Publication Number Publication Date
PL356261A1 true PL356261A1 (pl) 2004-06-28
PL201191B1 PL201191B1 (pl) 2009-03-31

Family

ID=10862304

Family Applications (1)

Application Number Title Priority Date Filing Date
PL356261A PL201191B1 (pl) 1999-10-07 2000-10-05 Piperazynowa pochodna i jej zastosowanie, zawierająca ją farmaceutyczna kompozycja oraz sposób wytwarzania piperazynowej pochodnej

Country Status (33)

Country Link
US (6) US6951861B1 (pl)
EP (3) EP1460066B1 (pl)
JP (1) JP4776844B2 (pl)
KR (2) KR100817373B1 (pl)
CN (1) CN100413850C (pl)
AR (2) AR025975A1 (pl)
AT (3) ATE407125T1 (pl)
AU (1) AU768780B2 (pl)
BR (1) BR0014541A (pl)
CA (1) CA2386515C (pl)
CO (1) CO5251467A1 (pl)
CY (2) CY1110172T1 (pl)
CZ (1) CZ302340B6 (pl)
DE (3) DE60042501D1 (pl)
DK (3) DK1460066T3 (pl)
ES (3) ES2312917T3 (pl)
GB (1) GB9923748D0 (pl)
HK (1) HK1052506B (pl)
HU (1) HUP0203136A3 (pl)
IL (2) IL148964A0 (pl)
MX (1) MXPA02003515A (pl)
MY (1) MY130907A (pl)
NO (1) NO323776B1 (pl)
NZ (2) NZ518144A (pl)
PE (1) PE20010741A1 (pl)
PL (1) PL201191B1 (pl)
PT (3) PT1218359E (pl)
SI (3) SI1454901T1 (pl)
TN (1) TNSN00194A1 (pl)
TR (1) TR200200936T2 (pl)
TW (1) TWI225485B (pl)
WO (1) WO2001025219A2 (pl)
ZA (1) ZA200202589B (pl)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE434437T1 (de) * 1999-02-18 2009-07-15 Novasearch Ag Verwendung von antagonisten der 5-ht3-rezeptoren zur behandlung von muskuloeskeletalen erkrankungen
USRE39921E1 (en) 1999-10-07 2007-11-13 Smithkline Beecham Corporation Chemical compounds
GB9923748D0 (en) * 1999-10-07 1999-12-08 Glaxo Group Ltd Chemical compounds
AUPQ514600A0 (en) 2000-01-18 2000-02-10 James Cook University Brain injury treatment
GB0003232D0 (en) * 2000-02-11 2000-04-05 Smithkline Beecham Plc Novel composition
GB0025354D0 (en) 2000-10-17 2000-11-29 Glaxo Group Ltd Chemical compounds
GB0108594D0 (en) * 2001-04-05 2001-05-23 Glaxo Group Ltd Chemical compounds
GB0108595D0 (en) 2001-04-05 2001-05-23 Glaxo Group Ltd Chemical compounds
US20030083345A1 (en) * 2001-07-10 2003-05-01 Torsten Hoffmann Method of treatment and/or prevention of brain, spinal or nerve injury
GB0119797D0 (en) 2001-08-14 2001-10-03 Glaxo Group Ltd Chemical compounds
GB0124463D0 (en) 2001-10-11 2001-12-05 Smithkline Beecham Plc Compounds
GB0203022D0 (en) 2002-02-08 2002-03-27 Glaxo Group Ltd Chemical compounds
GB0203020D0 (en) * 2002-02-08 2002-03-27 Glaxo Group Ltd Chemical compounds
US7482365B2 (en) 2002-02-08 2009-01-27 Glaxo Group Limited Piperidylcarboxamide derivatives and their use in the treatment of tachykinin-mediated diseases
DE10209145A1 (de) * 2002-03-01 2003-09-04 Bayer Cropscience Ag Halogenbenzole
WO2003101459A1 (en) * 2002-05-29 2003-12-11 The Regents Of The University Of California Antagonizing nk1 receptors inhibits consumption of substances of abuse
JP4079727B2 (ja) * 2002-09-06 2008-04-23 セントラル硝子株式会社 光学活性１−（フルオロ、トリフルオロメチルまたはトリフルオロメトキシ置換フェニル）アルキルアミンｎ−モノアルキル誘導体とその製造方法
EP1594574A2 (en) * 2003-01-27 2005-11-16 Glaxo Group Limited Nk1 receptor antagonists for the treatment of functional dyspepsia
GB0308968D0 (en) * 2003-04-17 2003-05-28 Glaxo Group Ltd Medicaments
JP2006527756A (ja) * 2003-06-19 2006-12-07 ファイザー・プロダクツ・インク Ｎｋ１拮抗薬
US20060148783A1 (en) * 2003-11-10 2006-07-06 Lundeen James E Method and medicine for treating gastrointestinal disorder including fecal incontinence
US20070142367A1 (en) * 2003-11-10 2007-06-21 Lundeen James E Method and medicine for treating gastrointestinal disorder including fecal incontinence
US20050113365A1 (en) * 2003-11-10 2005-05-26 Sir Isaac Newton Enterprises Llc Method and medicine for treating gastrointestinal disorder including irritable bowel syndrome
US20060148782A1 (en) * 2003-11-10 2006-07-06 Lundeen James E Method and medicine for treating a mammal presenting urinary incontinence, urinary urgency, or both
US20060148781A1 (en) * 2003-11-10 2006-07-06 Lundeen James E Method and medicine for treating gastrointestinal disorder in a non-human mammal
CA2547467A1 (en) * 2003-11-28 2005-06-09 Tanabe Seiyaku Co., Ltd. Piperidine compound and method for producing same
CA2552965A1 (en) * 2004-01-14 2005-07-28 Takeda Pharmaceutical Company Limited Carboxamide derivative and use thereof
EP1943216B1 (en) * 2005-10-10 2010-06-30 Glaxo Group Limited Prolinamide derivatives as sodium channel modulators
TW200730494A (en) * 2005-10-10 2007-08-16 Glaxo Group Ltd Novel compounds
US20100009983A1 (en) * 2006-05-09 2010-01-14 Braincells, Inc. 5 ht receptor mediated neurogenesis
JP4904945B2 (ja) 2006-06-30 2012-03-28 セントラル硝子株式会社 光学活性１−（フルオロ、トリフルオロメチルまたはトリフルオロメトキシ置換フェニル）アルキルアミンｎ−モノアルキル誘導体の製造方法
GB0621229D0 (en) * 2006-10-20 2006-12-06 Glaxo Group Ltd Novel use
US20100105688A1 (en) 2007-01-24 2010-04-29 Glaxo Group Limited Pharmaceutical compositions comprising 3,5-diamino-6-(2,3-dichlophenyl)-1,2,4-triazine or r(-)-2,4-diamino-5-(2,3-dichlorophenyl)-6-fluoromethyl pyrimidine and an nk1
JP5510040B2 (ja) * 2010-04-28 2014-06-04 セントラル硝子株式会社 光学活性（ｒ）−１−（４−フルオロフェニル）エチルアミンを得る光学分割
WO2012175434A1 (en) 2011-06-20 2012-12-27 Glaxo Group Limited Pharmaceutical formulations comprising vestipitant
NO2729147T3 (pl) 2011-07-04 2018-02-03
CN104245702B (zh) * 2012-02-22 2016-09-14 利奥制药有限公司 新型神经激肽1受体拮抗剂化合物
WO2015024203A1 (en) 2013-08-20 2015-02-26 Leo Pharma A/S Novel neurokinin 1 receptor antagonist compounds ii
EP3237379B1 (en) 2014-12-23 2022-04-06 Convergence Pharmaceuticals Limited Process for preparing alpha-carboxamide pyrrolidine derivatives
JPWO2017099049A1 (ja) * 2015-12-07 2018-09-27 キッセイ薬品工業株式会社 Ｎｋ１受容体拮抗剤
IL312486B2 (en) 2017-04-10 2025-05-01 Chase Therapeutics Corp NK1 antagonist combination and method for treating synucleinopathies
JP7158425B2 (ja) 2017-06-30 2022-10-21 チェイス セラピューティクス コーポレイション Ｎｋ－１アンタゴニスト組成物およびうつ病の処置における使用法
WO2019071162A2 (en) 2017-10-05 2019-04-11 Biogen Inc. PROCESS FOR THE PREPARATION OF PYRROLIDINE ALPHA-CARBOXAMIDE DERIVATIVES

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1334812A (en) * 1919-07-23 1920-03-23 Theodore T Snow Post
US4219554A (en) 1974-05-09 1980-08-26 Toyama Chemical Company, Limited Novel penicillins and cephalosporins and process for producing same
US4327097A (en) 1974-05-09 1982-04-27 Toyama Chemical Co., Ltd. Novel penicillins
US4379152A (en) 1974-05-09 1983-04-05 Toyama Chemical Co., Ltd. Cephalosporins
US4110327A (en) 1974-05-09 1978-08-29 Toyama Chemical Co., Ltd. 2,3 Diketo-piperazinocarbonylamino alkanoic acids and derivatives
US4410522A (en) 1974-05-09 1983-10-18 Toyama Chemical Co., Ltd. Cephalosporins
US4112090A (en) 1974-05-09 1978-09-05 Toyama Chemical Co., Ltd. Novel penicillins and cephalosporins and process for producing the same
US4087424A (en) 1974-05-09 1978-05-02 Toyama Chemical Co., Ltd. Novel penicillins and cephalosporins and process for producing the same
IL47168A (en) 1974-05-09 1979-07-25 Toyama Chemical Co Ltd Mono or dioxo piperazino(thio)carbonylamino derivatives ofpenicillins and cephalosporins and process for producing the same
NO154582C (no) 1978-10-20 1986-11-05 Ferrosan Ab Analogifremgangsmaate for fremstilling av terapeutisk aktive difenyl-dibutylpiperazinkarboksamider.
JPS57118587A (en) 1981-11-26 1982-07-23 Toyama Chem Co Ltd Novel penicillin
US5028610A (en) 1987-03-18 1991-07-02 Sankyo Company Limited N-benzhydryl-substituted heterocyclic derivatives, their preparation and their use
GB8709666D0 (en) 1987-04-23 1987-05-28 Beecham Group Plc Compounds
GB8713061D0 (en) 1987-06-04 1987-07-08 Beecham Group Plc Compounds
US5109014A (en) 1990-12-10 1992-04-28 Jacobson Richard M N-aryl-3-aryl-4-substituted-2,3,4,5-tetrahydro-1H-pyrazole-1-carboxamides
SE9100860D0 (sv) 1991-03-22 1991-03-22 Kabi Pharmacia Ab New use
EP1082959A1 (en) 1991-09-20 2001-03-14 Glaxo Group Limited NK1 Antagonists for the treatment of depression
EP0545478A1 (en) 1991-12-03 1993-06-09 MERCK SHARP & DOHME LTD. Heterocyclic compounds as tachykinin antagonists
US5563127A (en) 1993-03-24 1996-10-08 The Dupont Merck Pharmaceutical Company Boronic acid and ester inhibitors of thrombin
US5348955A (en) 1993-06-22 1994-09-20 Merck & Co., Inc. N,N-diacylpiperazines
IL111730A (en) 1993-11-29 1998-12-06 Fujisawa Pharmaceutical Co Piperazine derivatives processes for the preparation thereof and pharmaceutical compositions containing the same
IL112778A0 (en) 1994-03-04 1995-05-26 Merck & Co Inc Substituted heterocycles, their preparation and pharmaceutical compositions containing them
US5464788A (en) 1994-03-24 1995-11-07 Merck & Co., Inc. Tocolytic oxytocin receptor antagonists
DE4425146A1 (de) 1994-07-15 1996-01-18 Basf Ag Verwendung heterocyclischer Verbindungen
WO1996003378A1 (en) 1994-07-26 1996-02-08 Sankyo Company, Limited N-phenylated amide and urea derivatives
US5696123A (en) 1994-09-17 1997-12-09 Boehringer Ingelheim Kg Neurokinin antagonists
DE19520499C2 (de) 1994-09-17 2003-06-18 Boehringer Ingelheim Kg Neurokinin-Antagonisten, Verfahren zu ihrer Herstellung, diese Verbindungen enthaltende pharmazeutische Zusammensetzungen sowie ihre Verwendung
DE69534213T2 (de) 1994-10-25 2006-01-12 Astrazeneca Ab Therapeutisch wirksame Heterocyclen
US5998444A (en) 1995-10-24 1999-12-07 Zeneca Ltd. Piperidinyl compounds as NK1 or NK2 antagonists
US5629322A (en) 1994-11-15 1997-05-13 Merck & Co., Inc. Cyclic amidine analogs as inhibitors of nitric oxide synthase
US5576317A (en) 1994-12-09 1996-11-19 Pfizer Inc. NK-1 receptor antagonists and 5HT3 receptor antagonists for the treatment of emesis
US5700801A (en) 1994-12-23 1997-12-23 Karl Thomae, Gmbh Piperazine derivatives, pharmaceutical compositions containing these compounds, their use and processes for preparing them
PL321003A1 (en) 1994-12-23 1997-11-24 Thomae Gmbh Dr K Derivatives of piperasine, drugs containing them, their application and methods of obtaining them
NZ321575A (en) 1995-10-30 1999-05-28 Janssen Pharmaceutica Nv 1-(1,2-disubstituted piperidinyl)-4- substituted piperazine derivatives
DE19608665A1 (de) 1996-03-06 1997-09-11 Boehringer Ingelheim Kg Neue Arylglycinamidderivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende pharmazeutische Zusammensetzungen
US6057323A (en) 1996-03-08 2000-05-02 Adolor Corporation Kappa agonist compounds pharmaceutical formulations and method of prevention and treatment of pruritus therewith
JP2000507576A (ja) 1996-04-03 2000-06-20 メルク エンド カンパニー インコーポレーテッド ファルネシル―タンパク質トランスフェラーゼ阻害剤
JP2000507579A (ja) 1996-04-03 2000-06-20 メルク エンド カンパニー インコーポレーテッド ファルネシル―タンパク質トランスフェラーゼ阻害剤
US5859012A (en) 1996-04-03 1999-01-12 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
JP2000507582A (ja) 1996-04-03 2000-06-20 メルク エンド カンパニー インコーポレーテッド ファルネシルプロテイントランスフェラーゼの阻害剤
WO1998001133A1 (en) 1996-07-08 1998-01-15 Yamanouchi Pharmaceutical Co., Ltd. Bone resorption inhibitors
DE69728883T2 (de) * 1996-07-17 2005-04-07 Merck & Co., Inc. Änderung des zirkadischen rhythmus mit nicht-peptidischen neurokinin-1 rezeptor antagonisten
US6117855A (en) 1996-10-07 2000-09-12 Merck Sharp & Dohme Ltd. Use of a NK-1 receptor antagonist and an antidepressant and/or an anti-anxiety agent
US5929077A (en) 1996-11-08 1999-07-27 Leftheris; Katerina Thioproline-containing inhibitors of farnesyl protein transferase
US5977104A (en) 1996-12-02 1999-11-02 Merck Sharp & Dohme Ltd. Use of NK-1 receptor antagonists for treating bipolar disorders
US6114315A (en) 1996-12-02 2000-09-05 Merck Sharp & Dohme Ltd. Use of NK-1 receptor antagonists for treating major depressive disorders with anxiety
CA2273856A1 (en) 1996-12-02 1998-06-11 Merck Sharp & Dohme Limited Use of nk-1 receptor antagonists for treating bipolar disorders
AUPO735997A0 (en) 1997-06-17 1997-07-10 Fujisawa Pharmaceutical Co., Ltd. Piperazine derivatives
WO1999009985A1 (en) 1997-08-27 1999-03-04 Merck & Co., Inc. Inhibitors of prenyl-protein transferase
WO1999026921A1 (en) 1997-11-24 1999-06-03 Merck & Co., Inc. SUBSTITUTED β-ALANINE DERIVATIVES AS CELL ADHESION INHIBITORS
AU768652B2 (en) * 1998-12-14 2003-12-18 Astellas Pharma Inc. Piperazine derivatives
GB9923748D0 (en) * 1999-10-07 1999-12-08 Glaxo Group Ltd Chemical compounds
AU7788500A (en) * 1999-10-25 2001-05-08 Janssen Pharmaceutica N.V. Use of substance p antagonists for influencing the circadian timing system
GB0025354D0 (en) 2000-10-17 2000-11-29 Glaxo Group Ltd Chemical compounds
US20030022891A1 (en) 2000-12-01 2003-01-30 Anandan Palani MCH antagonists and their use in the treatment of obesity
MY141736A (en) 2002-10-08 2010-06-15 Elanco Animal Health Ireland Substituted 1,4-di-piperidin-4-yi-piperazine derivatives and their use as neurokinin antagonists

Also Published As

Publication number Publication date
AR025975A1 (es) 2002-12-26
US20040048862A1 (en) 2004-03-11
CO5251467A1 (es) 2003-02-28
DE60012031T2 (de) 2005-07-07
US7345041B2 (en) 2008-03-18
EP1454901B1 (en) 2008-09-03
KR100857671B1 (ko) 2008-09-08
DK1454901T3 (da) 2009-01-12
NO20021637L (no) 2002-06-06
US7625904B2 (en) 2009-12-01
DE60012031D1 (de) 2004-08-12
ATE407125T1 (de) 2008-09-15
PT1460066E (pt) 2009-09-10
JP2003511377A (ja) 2003-03-25
MY130907A (en) 2007-07-31
HK1052506A1 (zh) 2003-09-19
NO323776B1 (no) 2007-07-02
CY1110104T1 (el) 2015-01-14
AR077414A2 (es) 2011-08-24
EP1218359A2 (en) 2002-07-03
KR100817373B1 (ko) 2008-03-27
MXPA02003515A (es) 2002-09-02
SI1460066T1 (sl) 2009-12-31
US20040209893A1 (en) 2004-10-21
PT1454901E (pt) 2008-12-12
SI1218359T1 (en) 2005-02-28
NZ518144A (en) 2004-04-30
HUP0203136A3 (en) 2003-03-28
KR20070112308A (ko) 2007-11-22
ES2329130T3 (es) 2009-11-23
ATE435215T1 (de) 2009-07-15
EP1454901A1 (en) 2004-09-08
DK1218359T3 (da) 2004-10-18
CZ302340B6 (cs) 2011-03-23
ES2222927T3 (es) 2005-02-16
BR0014541A (pt) 2002-09-17
NZ531127A (en) 2005-11-25
DE60042501D1 (de) 2009-08-13
WO2001025219A3 (en) 2001-12-13
CN1391564A (zh) 2003-01-15
DK1460066T3 (da) 2009-11-02
ATE270664T1 (de) 2004-07-15
CN100413850C (zh) 2008-08-27
AU768780B2 (en) 2004-01-08
ZA200202589B (en) 2003-08-27
HK1065798A1 (en) 2005-03-04
US7071196B2 (en) 2006-07-04
JP4776844B2 (ja) 2011-09-21
EP1460066A1 (en) 2004-09-22
DE60040176D1 (de) 2008-10-16
US20080249108A1 (en) 2008-10-09
ES2312917T3 (es) 2009-03-01
HK1052506B (zh) 2008-12-19
US20030028021A1 (en) 2003-02-06
HUP0203136A2 (hu) 2003-02-28
CA2386515C (en) 2011-06-07
HK1066537A1 (en) 2005-03-24
US6951861B1 (en) 2005-10-04
AU7913900A (en) 2001-05-10
CA2386515A1 (en) 2001-04-12
EP1460066B1 (en) 2009-07-01
TNSN00194A1 (en) 2005-11-10
WO2001025219A2 (en) 2001-04-12
TWI225485B (en) 2004-12-21
EP1218359B1 (en) 2004-07-07
PE20010741A1 (es) 2001-07-18
NO20021637D0 (no) 2002-04-05
US20060122192A1 (en) 2006-06-08
KR20020038800A (ko) 2002-05-23
IL148964A0 (en) 2002-11-10
PL201191B1 (pl) 2009-03-31
GB9923748D0 (en) 1999-12-08
PT1218359E (pt) 2004-10-29
TR200200936T2 (tr) 2002-07-22
US6642240B2 (en) 2003-11-04
CZ20021166A3 (cs) 2002-11-13
CY1110172T1 (el) 2015-01-14
SI1454901T1 (sl) 2009-02-28
IL148964A (en) 2007-02-11

Similar Documents

Publication Publication Date Title
IL148964A0 (en) Piperazine compounds
PL352911A1 (pl) Nowe związki
GB2357761B (en) Compounds
PL354360A1 (pl) Nowe związki
PL356140A1 (pl) Nowe związki
GB9904930D0 (en) Thiazoloindolinone compounds
GB9908828D0 (en) Compounds
GB9902399D0 (en) Compounds
GB9914821D0 (en) Compounds
HUP9904624D0 (en) New compounds
GB9916647D0 (en) Compounds
SI1202994T1 (en) New compounds
GB9907454D0 (en) Compounds
GB9914376D0 (en) Compounds
GB9910711D0 (en) Compounds
GB9909840D0 (en) Compounds
GB9909839D0 (en) Compounds
GB9909803D0 (en) Compounds
GB9909474D0 (en) Compounds
GB9908931D0 (en) Compounds
GB9912982D0 (en) Compounds
GB9907456D0 (en) Compounds
GB9913821D0 (en) Compounds
GB9906278D0 (en) Compounds
GB9913823D0 (en) Compounds